Stabilization of symptomatic carotid atherosclerotic plaques by statins: a clinico-pathological analysis | springermedicine.com

Springer Medicine

Top

Heart and Vessels

Published in:

Open Access 01-11-2018 | Original Article

Stabilization of symptomatic carotid atherosclerotic plaques by statins: a clinico-pathological analysis

Authors: Takao Konishi, Naohiro Funayama, Tadashi Yamamoto, Daisuke Hotta, Ryota Nomura, Yusuke Nakagaki, Takeo Murahashi, Kenji Kamiyama, Tetsuyuki Yoshimoto, Takeshi Aoki, Shinya Tanaka

Published in: Heart and Vessels | Issue 11/2018

Login to get access

Abstract

Human and animal studies have revealed a stabilization of atherosclerotic plaques by statins. However, the stabilization of human carotid plaques has not been thoroughly described pathologically. This analysis explored the relationship between statin therapy and plaque stability in carotid endarterectomy (CEA) specimens. We analyzed specimens harvested between May 2015 and February 2017, from 79 consecutive patients presenting with > 70% carotid artery stenoses, of whom 66 were untreated (group 1) and 13 treated (group 2) with a statin. Immunohistochemistry was performed, using an endothelial specific antibody to CD31, CD34 and platelet derived growth factor receptor-β. The prevalence of plaque ruptures (P = 0.009), lumen thrombi (P = 0.009), inflammatory cells (P = 0.008), intraplaque hemorrhages (P = 0.030) and intraplaque microvessels (P < 0.001) was significantly lower in group 2 than in group 1. Among 66 patients presenting with strokes and infarct sizes > 1.0 cm³ on magnetic resonance imaging, the mean infarct volume was significantly smaller (P = 0.031) in group 2 (4.2 ± 2.5 cm³) than in group 1 (8.2 ± 7.1 cm³). The difference in mean concentration of low-density lipoprotein cholesterol between group 1 (121 ± 32 mg/dl) and group 2 (105 ± 37 mg/dl) was non-significant (P = 0.118). This analysis of plaques harvested from patients undergoing CEA suggests that statin therapy mitigates the plaque instability, which, in patients presenting with strokes, might decrease infarct volume.

Available only for authorised users

1.

Balk EM, Karas RH, Jordan HS, Kupelnick B, Chew P, Lau J (2004) Effects of statins on vascular structure and function: a systematic review. Am J Med 117:775–790CrossRef

2.

Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Stroke Prevention by Aggressive Reduction in Cholesterol Levels I (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549–559CrossRef

3.

Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670–1681CrossRef

4.

Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, Diaz C, Hernandez G, Egido J (1998) HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32:2057–2064CrossRef

5.

Bartoli M, Al-Shabrawey M, Labazi M, Behzadian MA, Istanboli M, El-Remessy AB, Caldwell RW, Marcus DM, Caldwell RB (2009) HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 50:4934–4940CrossRef

6.

Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B (1994) Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 90:1679–1687CrossRef

7.

Amarenco P, Labreuche J, Lavallee P, Touboul PJ (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35:2902–2909CrossRef

8.

Watanabe K, Sugiyama S, Kugiyama K, Honda O, Fukushima H, Koga H, Horibata Y, Hirai T, Sakamoto T, Yoshimura M, Yamashita Y, Ogawa H (2005) Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 46:2022–2030CrossRef

9.

Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, Subramanian SS, Abdelbaky A, Rudd JH, Farkouh ME, Nunes IO, Beals CR, Shankar SS (2013) Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol 62:909–917CrossRef

10.

Ibrahimi P, Jashari F, Bajraktari G, Wester P, Henein MY (2015) Ultrasound assessment of carotid plaque echogenicity response to statin therapy: a systematic review and meta-analysis. Int J Mol Sci 16:10734–10747CrossRef

11.

Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM (2000) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20:1262–1275CrossRef

12.

Redgrave JN, Gallagher P, Lovett JK, Rothwell PM (2008) Critical cap thickness and rupture in symptomatic carotid plaques: the oxford plaque study. Stroke 39:1722–1729CrossRef

13.

Lovett JK, Gallagher PJ, Hands LJ, Walton J, Rothwell PM (2004) Histological correlates of carotid plaque surface morphology on lumen contrast imaging. Circulation 110:2190–2197CrossRef

14.

Redgrave JN, Lovett JK, Gallagher PJ, Rothwell PM (2006) Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study. Circulation 113:2320–2328CrossRef

15.

Howard DP, van Lammeren GW, Redgrave JN, Moll FL, de Vries JP, de Kleijn DP, de Borst GJ, Pasterkamp G, Rothwell PM (2013) Histological features of carotid plaque in patients with ocular ischemia versus cerebral events. Stroke 44:734–739CrossRef

16.

Howard DP, van Lammeren GW, Rothwell PM, Redgrave JN, Moll FL, de Vries JP, de Kleijn DP, den Ruijter HM, de Borst GJ, Pasterkamp G (2015) Symptomatic carotid atherosclerotic disease: correlations between plaque composition and ipsilateral stroke risk. Stroke 46:182–189CrossRef

17.

Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G (1993) Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 24:987–993CrossRef

18.

Gossl M, Yoon MH, Choi BJ, Rihal C, Tilford JM, Reriani M, Gulati R, Sandhu G, Eeckhout E, Lennon R, Lerman LO, Lerman A (2014) Accelerated coronary plaque progression and endothelial dysfunction: serial volumetric evaluation by IVUS. JACC Cardiovasc Imaging 7:103–104CrossRef

19.

Lerman A, Zeiher AM (2005) Endothelial function: cardiac events. Circulation 111:363–368CrossRef

20.

Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P (1995) The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332:488–493CrossRef

21.

Vita JA, Yeung AC, Winniford M, Hodgson JM, Treasure CB, Klein JL, Werns S, Kern M, Plotkin D, Shih WJ, Mitchel Y, Ganz P (2000) Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 102:846–851CrossRef

22.

Beckman JA, Liao JK, Hurley S, Garrett LA, Chui D, Mitra D, Creager MA (2004) Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 95:217–223CrossRef

23.

Laufs U, La Fata V, Plutzky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129–1135CrossRef

24.

Gonzalez-Fernandez F, Jimenez A, Lopez-Blaya A, Velasco S, Arriero MM, Celdran A, Rico L, Farre J, Casado S, Lopez-Farre A (2001) Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins. Atherosclerosis 155:61–70CrossRef

25.

Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H (2001) Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 21:449–454CrossRef

26.

Daemen MJ, Ferguson MS, Gijsen FJ, Hippe DS, Kooi ME, Demarco K, van der Wal AC, Yuan C, Hatsukami TS (2016) Carotid plaque fissure: An underestimated source of intraplaque hemorrhage. Atherosclerosis 254:102–108CrossRef

27.

Konishi T, Funayama N, Yamamoto T, Morita T, Hotta D, Nomura R, Nakagaki Y, Murahashi T, Kamiyama K, Yoshimoto T, Aoki T, Nishihara H, Tanaka S (2017) Pathological quantification of carotid artery plaque instability in patients undergoing carotid endarterectomy. Circ J 82:258–266CrossRef

28.

Michel JB, Virmani R, Arbustini E, Pasterkamp G (2011) Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur Heart J 32:1977–1985, 1985a, 1985b, 1985cCrossRef

29.

Jeney V, Balla G, Balla J (2014) Red blood cell, hemoglobin and heme in the progression of atherosclerosis. Front Physiol 5:379CrossRef

30.

Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R (2003) Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349:2316–2325CrossRef

31.

Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J (2005) Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 25:2054–2061CrossRef

32.

Smith NL, Harrington LB, Blondon M, Wiggins KL, Floyd JS, Sitlani CM, McKnight B, Larson EB, Rosendaal FR, Heckbert SR, Psaty BM (2016) The association of statin therapy with the risk of recurrent venous thrombosis. J Thromb Haemost 14:1384–1392CrossRef

33.

Kunutsor SK, Seidu S, Khunti K (2017) Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol 4:e83–e93CrossRef

34.

Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360:1851–1861CrossRef

35.

Cortellaro M, Cofrancesco E, Arbustini E, Rossi F, Negri A, Tremoli E, Gabrielli L, Camera M (2002) Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 88:41–47CrossRef

36.

Eto M, Kozai T, Cosentino F, Joch H, Luscher TF (2002) Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105:1756–1759CrossRef

37.

Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, Miyamori I (2003) Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 23:512–517CrossRef

38.

McLean DL, Kim J, Kang Y, Shi H, Atkins GB, Jain MK, Chun HJ (2012) Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells—brief report. Arterioscler Thromb Vasc Biol 32:2640–2643CrossRef

39.

Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A (2001) Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 103:2248–2253CrossRef

40.

Sahebkar A, Ponziani MC, Goitre I, Bo S (2015) Does statin therapy reduce plasma VEGF levels in humans? A systematic review and meta-analysis of randomized controlled trials. Metabolism 64:1466–1476CrossRef

41.

Silvestre JS, Mallat Z, Tedgui A, Levy BI (2008) Post-ischaemic neovascularization and inflammation. Cardiovasc Res 78:242–249CrossRef

42.

Koutouzis M, Nomikos A, Nikolidakis S, Tzavara V, Andrikopoulos V, Nikolaou N, Barbatis C, Kyriakides ZS (2007) Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis 192:457–463CrossRef

43.

Libby P, Tabas I, Fredman G, Fisher EA (2014) Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 114:1867–1879CrossRef

44.

Molloy KJ, Thompson MM, Schwalbe EC, Bell PR, Naylor AR, Loftus IM (2004) Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively. Am J Cardiol 94:144–146CrossRef

45.

Schonbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109:II18–II26CrossRef

46.

Laufs U, Fata VL, Liao JK (1997) Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272:31725–31729CrossRef

47.

Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, Moskowitz MA, Liao JK (2005) Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36:2251–2257CrossRef

48.

Ni Chroinin D, Callaly EL, Duggan J, Merwick A, Hannon N, Sheehan O, Marnane M, Horgan G, Williams EB, Harris D, Kyne L, McCormack PM, Moroney J, Grant T, Williams D, Daly L, Kelly PJ (2011) Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke 42:1021–1029CrossRef

49.

Ni Chroinin D, Asplund K, Asberg S, Callaly E, Cuadrado-Godia E, Diez-Tejedor E, Di Napoli M, Engelter ST, Furie KL, Giannopoulos S, Gotto AM Jr, Hannon N, Jonsson F, Kapral MK, Marti-Fabregas J, Martinez-Sanchez P, Milionis HJ, Montaner J, Muscari A, Pikija S, Probstfield J, Rost NS, Thrift AG, Vemmos K, Kelly PJ (2013) Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke 44:448–456CrossRef

50.

Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, Sukhova GK, Libby P (1998) Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 97:2433–2444CrossRef

51.

Kitagawa K, Hosomi N, Nagai Y, Kagimura T, Ohtsuki T, Origasa H, Minematsu K, Uchiyama S, Nakamura M, Matsumoto M, Investigators JS (2017) Reduction in high-sensitivity C-reactive protein levels in patients with ischemic stroke by statin treatment: Hs-CRP sub-study in J-STARS. J Atheroscler Thromb 24:1039–1047CrossRef

Title: Stabilization of symptomatic carotid atherosclerotic plaques by statins: a clinico-pathological analysis
Authors: Takao Konishi
Naohiro Funayama
Tadashi Yamamoto
Daisuke Hotta
Ryota Nomura
Yusuke Nakagaki
Takeo Murahashi
Kenji Kamiyama
Tetsuyuki Yoshimoto
Takeshi Aoki
Shinya Tanaka
Publication date: 01-11-2018
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 11/2018
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-018-1193-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties